small Cajal body-specific RNA 9Genealiases: Z32 · mgU2-19/30
Q-omics provides the consensus-scored SCARNA9 profile across patient tissues and cancer cell-line models. SCARNA9 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SCARNA9 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, SCARNA9 RNA expression shows 13,818 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, COAD, and UVM as cancer lineages where SCARNA9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCARNA9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCARNA9 survival associations across molecular data types. SCARNA9 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCARNA9 RNA expression–survival associations across cancer types. High SCARNA9 expression shows unfavorable associations in COAD, KIRC and READ, but favorable associations in UCEC, SKCM and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SCARNA9 RNA expression.
This table summarizes SCARNA9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SCARNA9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCARNA9 shows lower tumor expression in HNSC and BRCA and higher tumor expression in COAD, LIHC, THCA and KICH. The COAD box plot shows higher SCARNA9 RNA expression in tumor versus normal tissue (log2 FC = +1.605, t-test p < 0.001).
This table shows molecular features associated with SCARNA9 in patient tissues and cancer cell lines. In patient samples, SCARNA9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
